26 results on '"Kaushal Asrani"'
Search Results
2. Supplementary Figure 3 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 72K, Figure S3. Fn14 expression is elevated in letrozole-resistant MCF7 cells and NIH3T3 cells stably overexpressing HER2.
- Published
- 2023
3. Supplementary Figure 5 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 514K, Figure S5. U0126 or Wortmannin treatment of MCF7/HER2 and AU565 cells decreases Fn14 expression.
- Published
- 2023
4. Supplementary Figure 6 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 30K, Figure S6. HRG1-β1 stimulation of MCF7 cells induces Fn14 mRNA expression.
- Published
- 2023
5. Supplementary Figure 4 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 111K, Figure S4. Lapatinib treatment or HER2/HER3 siRNA co-transfection of MCF7/HER2-18 cells decreases Fn14 expression levels.
- Published
- 2023
6. Supplementary Figure Legend from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 103K
- Published
- 2023
7. Data from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
HER2 overexpression occurs in 15% to 20% of all breast cancers and is associated with increased metastatic potential and poor patient survival. Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2–HER3 heterodimers and drives breast cancer cell growth and metastasis. In a previous study, we found that fibroblast growth factor-inducible 14 (Fn14), a member of the TNF receptor superfamily, was frequently overexpressed in human HER2+ breast tumors. We report here that HER2 and Fn14 are also coexpressed in mammary tumors that develop in two different transgenic mouse models of breast cancer. In consideration of these findings, we investigated whether HER2 activation in breast cancer cells could directly induce Fn14 gene expression. We found that transient or stable transfection of MCF7 cells with a HER2 expression plasmid increased Fn14 protein levels. Also, HRG1-β1 treatment of MCF7 cells transiently induced Fn14 mRNA and protein expression. Both the HER2- and HRG1-β1–induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA. We also report that Fn14-depleted, HER2-overexpressing MCF7 cells have reduced basal cell migration capacity and reduced HRG1-β1–stimulated cell migration, invasion, and matrix metalloproteinase (MMP)-9 expression. Together, these results indicate that Fn14 may be an important downstream regulator of HER2/HER3–driven breast cancer cell migration and invasion. Mol Cancer Res; 11(4); 393–404. ©2013 AACR.
- Published
- 2023
8. Supplementary Figure 2 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 26K, Figure S2. HER2 overexpression in MCF7 cells does not increase Fn14 mRNA expression.
- Published
- 2023
9. Supplementary Figure 1 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 308K, Figure S1. Analysis of Fn14 and EGFR family member expression in breast cancer cell lines.
- Published
- 2023
10. Supplementary Figure 7 from The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Jeffrey A. Winkles, Nhan L. Tran, Arundhati Ghosh, Sarah J. Morgan, Sharron A.N. Brown, Rebeca Galisteo, Ruth A. Keri, and Kaushal Asrani
- Abstract
PDF file - 177K, Figure S7. HRG1-β1 stimulation increases MCF7/HER2-18 cell migration and invasion.
- Published
- 2023
11. <scp>GPNMB</scp> expression identifies <scp>TSC1</scp> /2/ <scp>mTOR</scp> ‐associated and <scp>MiT</scp> family translocation‐driven renal neoplasms
- Author
-
Daniela C Salles, Kaushal Asrani, Juhyung Woo, Thiago Vidotto, Hans B Liu, Igor Vidal, Andres Matoso, George J Netto, Pedram Argani, and Tamara L Lotan
- Subjects
Male ,Membrane Glycoproteins ,Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ,Perivascular Epithelioid Cell Neoplasms ,TOR Serine-Threonine Kinases ,Mechanistic Target of Rapamycin Complex 1 ,Kidney Neoplasms ,Translocation, Genetic ,Pathology and Forensic Medicine ,Leukemia, Myeloid, Acute ,Mice ,Tuberous Sclerosis ,Biomarkers, Tumor ,Animals ,Humans ,Microphthalmos ,Female ,Eye Proteins ,Carcinoma, Renal Cell ,Transcription Factors - Abstract
GPNMB (glycoprotein nonmetastatic B) and other TFE3/TFEB transcriptional targets have been proposed as markers for microphthalmia (MiT) translocation renal cell carcinomas (tRCCs). We recently demonstrated that constitutive mTORC1 activation via TSC1/2 loss leads to increased activity of TFE3/TFEB, suggesting that the pathogenesis and molecular markers for tRCCs and TSC1/2-associated tumors may be overlapping. We examined GPNMB expression in human kidney and angiomyolipoma (AML) cell lines with TSC2 and/or TFE3/TFEB loss produced using CRISPR-Cas9 genome editing as well as in a mouse model of Tsc2 inactivation-driven renal tumorigenesis. Using an automated immunohistochemistry (IHC) assay for GPNMB, digital image analysis was employed to quantitatively score expression in clear cell RCC (ccRCC, n = 87), papillary RCC (papRCC, n = 53), chromophobe RCC (chRCC, n = 34), oncocytoma (n = 4), TFE3- or TFEB-driven tRCC (n = 56), eosinophilic solid and cystic RCC (ESC, n = 6), eosinophilic vacuolated tumor (EVT, n = 4), and low-grade oncocytic tumor (LOT, n = 3), as well as AML (n = 29) and perivascular epithelioid cell tumors (PEComas, n = 8). In cell lines, GPNMB was upregulated following TSC2 loss in a MiT/TFE- and mTORC1-dependent fashion. Renal tumors in Tsc2
- Published
- 2022
12. MicroRNA‐141‐3p regulates cellular proliferation, migration, and invasion in esophageal cancer by targeting tuberous sclerosis complex 1
- Author
-
James M. Donahue, Pornima Phatak, Michaël Noë, Ingrid E. Chesnick, Kaushal Asrani, and Bruce D. Greenwald
- Subjects
0301 basic medicine ,Cancer Research ,Esophageal Neoplasms ,Biology ,Tuberous Sclerosis Complex 1 Protein ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,microRNA ,medicine ,Humans ,Gene silencing ,Neoplasm Invasiveness ,RNA, Messenger ,3' Untranslated Regions ,Molecular Biology ,Cell Proliferation ,Laser capture microdissection ,Messenger RNA ,Binding Sites ,Oncogene ,RNA ,Esophageal cancer ,medicine.disease ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,TSC1 - Abstract
MicroRNA (miR)-141-3p, which functions as an oncogene in multiple malignancies, has been shown to be highly overexpressed in esophageal cancer cells in our previous work. miR-141-3p is predicted to bind the messenger RNA (mRNA) of tuberous sclerosis complex 1 (TSC1), a tumor suppressor, with high affinity. In this study, we investigated the expression and functional interaction between miR-141-3p and TSC1 in esophageal cancer cells. Experiments were conducted in four esophageal cancer lines and in tumor cells isolated from human esophageal cancer specimens by laser capture microdissection. miR-141-3p expression was measured by real time and droplet digital PCR. Biotinylated RNA pull-down and luciferase reporter assays were used to assess binding. miR-141-3p function was tested by assessing proliferation, migration, invasion, and induction of autophagy following its silencing. We found that miR-141-3p levels were increased in TE7, OE33, and TE10 esophageal cancer cells compared to FLO-1 cells, with similar heterogeneity observed in human esophageal cancer specimens. Silencing of miR-141-3p led to increased TSC1 protein expression in these cells and was associated with increased TSC1 translation. Binding studies reveal that miR-141-3p binds to each of the predicted binding sites in the 3'-untranslated region of TSC1 mRNA. Following miR-141-3p silencing, TE7, OE33, and TE10 cells exhibited decreased proliferation, migration, and invasion, as well as enhanced autophagy. Importantly, these phenotypic effects were replicated by overexpression of TSC1 alone in these cells. Our results indicate that miR-141-3p functions in an oncogenic capacity in a subset of esophageal cancer cells, in part by suppressing TSC1 expression.
- Published
- 2020
13. Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance
- Author
-
Iryna Samarska, Jonathan I. Epstein, Tamara L. Lotan, Harsimar B. Kaur, Mohamed Alshalalfa, Edward M. Schaeffer, Sanjana Murali, Jiayun Lu, Benjamin L. Maughan, Emmanuel S. Antonarakis, Corinne E. Joshu, Juan Miguel Mosquera, Farzana A. Faisal, and Kaushal Asrani
- Subjects
Male ,0301 basic medicine ,Ubiquitin-Protein Ligases ,Urology ,Adenocarcinoma ,Neuroendocrine differentiation ,Article ,Metastasis ,Cohort Studies ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Neuroendocrine Cells ,medicine ,Carcinoma ,Humans ,Enzalutamide ,PTEN ,Carcinoma, Small Cell ,Retrospective Studies ,biology ,business.industry ,PTEN Phosphohydrolase ,Prostatic Neoplasms ,Chromogranin A ,Cell Differentiation ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Neuroendocrine Tumors ,Prostatic Neoplasms, Castration-Resistant ,Retinoblastoma Binding Proteins ,030104 developmental biology ,Oncology ,chemistry ,Receptors, Androgen ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Tumor Suppressor Protein p53 ,business ,Signal Transduction - Abstract
BACKGROUND Small cell neuroendocrine (NE) carcinomas of the prostate classically lose androgen receptor (AR) expression, may harbor loss of the RB1, TP53, and PTEN tumor suppressor genes, and are associated with a poor prognosis. However usual-type adenocarcinomas may also contain areas of NE differentiation, and in this context the molecular features and biological significance are less certain. METHODS We examined the molecular phenotype and oncologic outcomes of primary prostate adenocarcinomas with ≥5% NE differentiation (≥5% chromogranin A-positive NE cells in any given tumor spot on tissue microarray) using three independent study sets: a set of tumors with paneth cell-like NE differentiation (n = 26), a retrospective case-cohort of intermediate- and high-risk patients enriched for adverse outcomes (n = 267), and primary tumors from a retrospective series of men with eventual castration-resistant metastatic prostate cancer (CRPC) treated with abiraterone or enzalutamide (n = 55). RESULTS Benign NE cells expressed significantly lower quantified AR levels compared with paired benign luminal cells (P
- Published
- 2020
14. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer
- Author
-
Angelo M. De Marzo, Tamara L. Lotan, Michael C. Haffner, Jun Luo, Alba Torres, Srinivasan Yegnasubramanian, Juhyung Woo, Ilsa Coleman, Thiago Vidotto, Brian Hanratty, Kaushal Asrani, Peter S. Nelson, Harrison Tsai, and Eva Corey
- Subjects
YAP1 ,Male ,YAP-Signaling Proteins ,Biology ,medicine.disease ,Article ,Pathology and Forensic Medicine ,Carcinoma, Neuroendocrine ,Androgen deprivation therapy ,Repressor Proteins ,Prostate cancer ,Mice ,Prostatic Neoplasms, Castration-Resistant ,Hippo signaling ,DNA methylation ,medicine ,Cancer research ,Biomarkers, Tumor ,Adenocarcinoma ,Gene silencing ,Animals ,Heterografts ,Humans ,Transcription factor - Abstract
Neuroendocrine prostate cancer (NEPC) is a rare but aggressive histologic variant of prostate cancer that responds poorly to androgen deprivation therapy. Hybrid NEPC-adenocarcinoma (AdCa) tumors are common, often eluding accurate pathologic diagnosis and requiring ancillary markers for classification. We recently performed an outlier-based meta-analysis across a number of independent gene expression microarray datasets to identify novel markers that differentiate NEPC from AdCa, including up-regulation of insulinoma-associated protein 1 (INSM1) and loss of Yes-associated protein 1 (YAP1). Here, using diverse cancer gene expression datasets, we show that Hippo pathway-related genes, including YAP1, are among the top down-regulated gene sets with expression of the neuroendocrine transcription factors, including INSM1. In prostate cancer cell lines, transgenic mouse models, and human prostate tumor cohorts, we confirm that YAP1 RNA and YAP1 protein expression are silenced in NEPC and demonstrate that the inverse correlation of INSM1 and YAP1 expression helps to distinguish AdCa from NEPC. Mechanistically, we find that YAP1 loss in NEPC may help to maintain INSM1 expression in prostate cancer cell lines and we further demonstrate that YAP1 silencing likely occurs epigenetically, via CpG hypermethylation near its transcriptional start site. Taken together, these data nominate two additional markers to distinguish NEPC from AdCa and add to data from other tumor types suggesting that Hippo signaling is tightly reciprocally regulated with neuroendocrine transcription factor expression. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Published
- 2021
15. mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation
- Author
-
Sanjana Murali, Brandon Lam, Ravi K. Anchoori, Pornima Phatak, Michael Skaro, Barbara S. Smith, Tamara L. Lotan, C. Conover Talbot, Harsimar B. Kaur, Zoya Khan, Michaël Noë, Chan Hyun Na, Akshay Sood, and Kaushal Asrani
- Subjects
Receptor, ErbB-2 ,Active Transport, Cell Nucleus ,Context (language use) ,mTORC1 ,Mechanistic Target of Rapamycin Complex 1 ,Receptor tyrosine kinase ,Tuberous Sclerosis Complex 1 Protein ,Mice ,Downregulation and upregulation ,Animals ,Promoter Regions, Genetic ,Transcription factor ,Protein kinase B ,Cells, Cultured ,Microphthalmia-Associated Transcription Factor ,biology ,Chemistry ,Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ,General Medicine ,Cell biology ,ErbB Receptors ,biology.protein ,biological phenomena, cell phenomena, and immunity ,Lysosomes ,Proto-Oncogene Proteins c-akt ,Biogenesis ,RHEB ,Research Article - Abstract
The microphthalmia family of transcription factors (MiT/TFEs) controls lysosomal biogenesis and is negatively regulated by the nutrient sensor mTORC1. However, the mechanisms by which cells with constitutive mTORC1 signaling maintain lysosomal catabolism remain to be elucidated. Using the murine epidermis as a model system, we found that epidermal Tsc1 deletion resulted in a phenotype characterized by wavy hair and curly whiskers, and was associated with increased EGFR and HER2 degradation. Unexpectedly, constitutive mTORC1 activation with Tsc1 loss increased lysosomal content via upregulated expression and activity of MiT/TFEs, whereas genetic deletion of Rheb or Rptor or prolonged pharmacologic mTORC1 inactivation had the reverse effect. This paradoxical increase in lysosomal biogenesis by mTORC1 was mediated by feedback inhibition of AKT, and a resulting suppression of AKT-induced MiT/TFE downregulation. Thus, inhibiting hyperactive AKT signaling in the context of mTORC1 loss-of-function fully restored MiT/TFE expression and activity. These data suggest that signaling feedback loops work to restrain or maintain cellular lysosomal content during chronically inhibited or constitutively active mTORC1 signaling, respectively, and reveal a mechanism by which mTORC1 regulates upstream receptor tyrosine kinase signaling.
- Published
- 2019
16. Abstract 2431: mTORC1 paradoxically drives MiT/TFE activity and lysosomal biogenesis in tuberous sclerosis complex
- Author
-
Tamara L. Lotan, Kaushal Asrani, Thiago Vidotto, Edward Gabrielson, Juhyung Woo, Adrianna A. Mendes, Daniela C. Salles, Sanjana Murali, and Pedram Argani
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Cancer Research ,Tuberous sclerosis ,Oncology ,medicine ,mTORC1 ,Biology ,medicine.disease ,Biogenesis ,Cell biology - Abstract
Background: Tuberous Sclerosis Complex (TSC) is characterized by TSC1/2 loss, dysregulated mTORC1 signaling & renal tumors (angiomyolipomas (AML) & renal cell carcinoma (RCC)). The MiT/TFE transcription factors (MITF/TFE3/TFEB) drive autophagy/lysosomal biogenesis & are negatively regulated by mTORC1. However, this model raises a paradox in cancer, where elevated lysosomal activity must persist with mTORC1 activity. We recently showed that epidermal Tsc1 loss paradoxically increases MiT/TFE-activity (https://www.jci.org/articles/view/128287). Intriguingly, TFE3/TFEB gene rearrangements/amplifications and TSC1/2 loss are mutually exclusive drivers in PEComas & RCC. This raises the possibility that TSC1/2 loss & TFE3/TFEB gene rearrangements have overlapping cellular consequences. Here, we address the hypothesis that MiT/TFE-driven lysosomal biogenesis drives tumorigenesis in TSC. Design: We used HEK293T cells +/- CRISPR deletion (KO) of TSC1, 2 or both, to examine: a) Lysosomal gene enrichment by RNA-seq/GSEA, b) Expression of MiT/TFE & lysosomal markers (immunoblotting, qRT-PCR & IF), c) MiT/TFE localization (IF & nuclear fraction immunoblots), d) MiT/TFE activity (4X-CLEAR luciferase assays, qRT-PCR, cathepsin processing, autophagic flux, LC3 puncta). We analysed spontaneous renal tumors in Tsc2 +/- mice for MIT/TFE protein/gene expression (IHC, IF & qRT-PCR analyses of laser capture micro-dissected (LCM) renal tumors). We examined MIT/TFE proteins/lysosomal markers in FFPE samples of renal PEComas & eosinophilic solid & cystic (ESC) RCC & normal kidney. Results: RNA-seq/GSEA showed enrichment of lysosomal gene sets in TSC1/2 KO cells compared to controls. TSC2 KO cells had increased expression of lysosomal transcripts & proteins in cellular lysates & lysosomal fractions. TSC1, 2 & 1/2 KO cells showed increased nuclear TFEB/TFE3 (IF/nuclear-fraction immunoblots), compared to controls. MiT/TFE activity in 4X-CLEAR luciferase reporter assays was increased in TSC2 KO cells compared to controls. Treatment of TSC2 KO cells with chloroquine increased lipidated LC3-II, indicating increased autophagic flux. TSC2 KO cells also showed increased LC3-labelled puncta by IF. We analyzed renal tumors in Tsc2 +/- mice, where elevated mTORC1 signaling was confirmed by p-S6 IHC. Expression of lysosomal proteins (LAMP1, Lamtor 1, Rag C, Cathepsin B) & nuclear localization of TFE3 & TFEB was increased in these lesions by IF/IHC, compared to normal kidney. We performed LCM on renal tumors from Tsc2 +/- mice & found levels of MiT/TFE transcriptional targets to be significantly enriched in tumors compared to normal kidney. We analyzed TFE3 expression in 10 cases of ESC- RCC with sporadic bi-allelic TSC1/2 mutations & 2 cases of TSC-associated RCC; 8/10 cases showed elevated nuclear TFE3. Conclusions: Elevated MiT/TFE levels & activity may represent oncogenic drivers in human & murine renal tumors in TSC. Citation Format: Kaushal V. Asrani, Daniela Salles, Juhyung Woo, Adrianna Mendes, Sanjana Murali, Thiago Vidotto, Pedram Argani, Edward Gabrielson, Tamara Lotan. mTORC1 paradoxically drives MiT/TFE activity and lysosomal biogenesis in tuberous sclerosis complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2431.
- Published
- 2021
17. mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation
- Author
-
Paul F. Worley, Amber Dubin, C. Conover Talbot, Alba Torres, Bo Xiao, Dan Georgess, Andrew J. Ewald, Pornima Phatak, Akshay Sood, Harsimar B. Kaur, Loubna Elhelu, Tamara L. Lotan, and Kaushal Asrani
- Subjects
Keratinocytes ,0301 basic medicine ,Cellular differentiation ,Receptor, Transforming Growth Factor-beta Type I ,Mechanistic Target of Rapamycin Complex 1 ,Protein Serine-Threonine Kinases ,03 medical and health sciences ,Downregulation and upregulation ,Transforming Growth Factor beta ,Cell Adhesion ,medicine ,Animals ,ROCK1 ,Cell adhesion ,Rho-associated protein kinase ,Cells, Cultured ,Mice, Knockout ,rho-Associated Kinases ,biology ,Chemistry ,Cell Differentiation ,Desmosomes ,General Medicine ,Cell biology ,Enzyme Activation ,Mice, Inbred C57BL ,030104 developmental biology ,medicine.anatomical_structure ,Epidermal Cells ,biology.protein ,Female ,biological phenomena, cell phenomena, and immunity ,Signal transduction ,Keratinocyte ,Receptors, Transforming Growth Factor beta ,Signal Transduction ,Research Article ,RHEB - Abstract
Despite its central position in oncogenic intracellular signaling networks, the role of mTORC1 in epithelial development has not been studied extensively in vivo. Here, we have used the epidermis as a model system to elucidate the cellular effects and signaling feedback sequelae of mTORC1 loss of function in epithelial tissue. In mice with conditional epidermal loss of the mTORC1 components Rheb or Rptor, mTORC1 loss of function unexpectedly resulted in a profound skin barrier defect with epidermal abrasions, blistering, and early postnatal lethality, due to a thinned epidermis with decreased desmosomal protein expression and incomplete biochemical differentiation. In mice with mTORC1 loss of function, we found that Rho kinase (ROCK) signaling was constitutively activated, resulting in increased cytoskeletal tension and impaired cell-cell adhesion. Inhibition or silencing of ROCK1 was sufficient to rescue keratinocyte adhesion and biochemical differentiation in these mice. mTORC1 loss of function also resulted in marked feedback upregulation of upstream TGF-β signaling, triggering ROCK activity and its downstream effects on desmosomal gene expression. These findings elucidate a role for mTORC1 in the regulation of epithelial barrier formation, cytoskeletal tension, and cell adhesion, underscoring the complexity of signaling feedback following mTORC1 inhibition.
- Published
- 2017
18. Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology
- Author
-
Matthew J. Weiss, Denis Wirtz, Matthew T. Olson, Kaushal Asrani, Michaël Noë, Seung-Mo Hong, Martin A. Makary, Sung Joo Kim, Neda Rezaee, Nicholas J. Roberts, Pei Hsun Wu, Jin He, Christopher L. Wolfgang, John L. Cameron, Laura D. Wood, G. Johan A. Offerhaus, Ralph H. Hruban, Vincent P. Groot, Lodewijk A.A. Brosens, and Michael Skaro
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Pancreatic Intraepithelial Neoplasia ,Article ,Pathology and Forensic Medicine ,03 medical and health sciences ,Cytokeratin ,Immunolabeling ,Imaging, Three-Dimensional ,medicine ,Carcinoma ,Humans ,Pancreas ,Microscopy, Confocal ,Intraductal papillary mucinous neoplasm ,Staining and Labeling ,business.industry ,Anatomy ,medicine.disease ,Adenocarcinoma, Mucinous ,Immunohistochemistry ,Pancreatic Neoplasms ,030104 developmental biology ,medicine.anatomical_structure ,Adenocarcinoma ,business ,Carcinoma, Pancreatic Ductal - Abstract
Visualizing pathologies in three dimensions can provide unique insights into the biology of human diseases. A rapid and easy-to-implement dibenzyl ether–based technique was used to clear thick sections of surgically resected human pancreatic parenchyma. Protocols were applicable to both fresh and formalin-fixed, paraffin-embedded tissue. The penetration of antibodies into dense pancreatic parenchyma was optimized using both gradually increasing antibody concentrations and centrifugal flow. Immunolabeling with antibodies against cytokeratin 19 was visualized using both light sheet and confocal laser scanning microscopy. The technique was applied successfully to 26 sections of pancreas, providing three-dimensional (3D) images of normal pancreatic tissue, pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms, and infiltrating pancreatic ductal adenocarcinomas. 3D visualization highlighted processes that are hard to conceptualize in two dimensions, such as invasive carcinoma growing into what appeared to be pre-existing pancreatic ducts and within venules, and the tracking of long cords of neoplastic cells parallel to blood vessels. Expanding this technique to formalin-fixed, paraffin-embedded tissue opens pathology archives to 3D visualization of unique biosamples and rare diseases. The application of immunolabeling and clearing to human pancreatic parenchyma provides detailed visualization of normal pancreatic anatomy, and can be used to characterize the 3D architecture of diseases including pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and pancreatic ductal adenocarcinomas.
- Published
- 2018
19. 429 mTORC1 feedback to AKT modulates MiT/TFE-driven lysosomal biogenesis and EGFR degradation
- Author
-
B. Lam, Michaël Noë, C. Na, Ravi K. Anchoori, Kaushal Asrani, Michael Skaro, Sanjana Murali, Tamara L. Lotan, Akshay Sood, C. Conover Talbot, Barbara S. Smith, Pornima Phatak, Harsimar B. Kaur, and Z. Khan
- Subjects
Chemistry ,Degradation (geology) ,Cell Biology ,Dermatology ,mTORC1 ,Molecular Biology ,Biochemistry ,Protein kinase B ,Biogenesis ,Cell biology - Published
- 2019
20. The HER2- and Heregulin β1 (HRG)–Inducible TNFR Superfamily Member Fn14 Promotes HRG-Driven Breast Cancer Cell Migration, Invasion, and MMP9 Expression
- Author
-
Rebeca Galisteo, Jeffrey A. Winkles, Ruth A. Keri, Arundhati Ghosh, Kaushal Asrani, Nhan L. Tran, Sarah J. Morgan, and Sharron A.N. Brown
- Subjects
Male ,Cancer Research ,Receptor, ErbB-2 ,Neuregulin-1 ,Breast Neoplasms ,Mice, Transgenic ,Biology ,Transfection ,Lapatinib ,Article ,Receptors, Tumor Necrosis Factor ,Metastasis ,Mice ,Breast cancer ,Cell Movement ,Gene expression ,medicine ,Animals ,Humans ,skin and connective tissue diseases ,Fibroblast ,neoplasms ,Molecular Biology ,Cancer ,Cell migration ,medicine.disease ,Disease Models, Animal ,medicine.anatomical_structure ,Matrix Metalloproteinase 9 ,Oncology ,TWEAK Receptor ,Cancer research ,Neuregulin ,Female ,medicine.drug - Abstract
HER2 overexpression occurs in 15% to 20% of all breast cancers and is associated with increased metastatic potential and poor patient survival. Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2–HER3 heterodimers and drives breast cancer cell growth and metastasis. In a previous study, we found that fibroblast growth factor-inducible 14 (Fn14), a member of the TNF receptor superfamily, was frequently overexpressed in human HER2+ breast tumors. We report here that HER2 and Fn14 are also coexpressed in mammary tumors that develop in two different transgenic mouse models of breast cancer. In consideration of these findings, we investigated whether HER2 activation in breast cancer cells could directly induce Fn14 gene expression. We found that transient or stable transfection of MCF7 cells with a HER2 expression plasmid increased Fn14 protein levels. Also, HRG1-β1 treatment of MCF7 cells transiently induced Fn14 mRNA and protein expression. Both the HER2- and HRG1-β1–induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA. We also report that Fn14-depleted, HER2-overexpressing MCF7 cells have reduced basal cell migration capacity and reduced HRG1-β1–stimulated cell migration, invasion, and matrix metalloproteinase (MMP)-9 expression. Together, these results indicate that Fn14 may be an important downstream regulator of HER2/HER3–driven breast cancer cell migration and invasion. Mol Cancer Res; 11(4); 393–404. ©2013 AACR.
- Published
- 2013
21. Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion
- Author
-
Timothy G. Whitsett, Emily Cheng, Kaushal Asrani, Jeffrey A. Winkles, Christopher Kingsley, Joseph C. Loftus, Ross M. Bremner, Nhan L. Tran, Galen Hostetter, Glen J. Weiss, Landon J. Inge, and Nathan M. Jameson
- Subjects
Lung Neoplasms ,Somatic cell ,Mice, SCID ,Biology ,Receptors, Tumor Necrosis Factor ,Pathology and Forensic Medicine ,Erlotinib Hydrochloride ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Carcinoma, Non-Small-Cell Lung ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,Epidermal growth factor receptor ,Phosphorylation ,Lung cancer ,Protein Kinase Inhibitors ,030304 developmental biology ,A549 cell ,0303 health sciences ,Gene knockdown ,Cancer ,Regular Article ,medicine.disease ,Neoplasm Proteins ,Rats ,respiratory tract diseases ,3. Good health ,ErbB Receptors ,Genes, ras ,TWEAK Receptor ,Gene Knockdown Techniques ,030220 oncology & carcinogenesis ,Mutation ,Quinazolines ,Cancer research ,biology.protein ,Signal transduction ,Neoplasm Transplantation ,Signal Transduction - Abstract
Lung cancer is the leading cause of cancer deaths worldwide; approximately 85% of these cancers are non-small cell lung cancer (NSCLC). Patients with NSCLC frequently have tumors harboring somatic mutations in the epidermal growth factor receptor (EGFR) gene that cause constitutive receptor activation. These patients have the best clinical response to EGFR tyrosine kinase inhibitors (TKIs). Herein, we show that fibroblast growth factor-inducible 14 (Fn14; TNFRSF12A) is frequently overexpressed in NSCLC tumors, and Fn14 levels correlate with p-EGFR expression. We also report that NSCLC cell lines that contain EGFR-activating mutations show high levels of Fn14 protein expression. EGFR TKI treatment of EGFR-mutant HCC827 cells decreased Fn14 protein levels, whereas EGF stimulation of EGFR wild-type A549 cells transiently increased Fn14 expression. Furthermore, Fn14 is highly expressed in EGFR-mutant H1975 cells that also contain an EGFR TKI-resistance mutation, and high TKI doses are necessary to reduce Fn14 levels. Constructs encoding EGFRs with activating mutations induced Fn14 expression when expressed in rat lung epithelial cells. We also report that short hairpin RNA-mediated Fn14 knockdown reduced NSCLC cell migration and invasion in vitro. Finally, Fn14 overexpression enhanced NSCLC cell migration and invasion in vitro and increased experimental lung metastases in vivo. Thus, Fn14 may be a novel therapeutic target for patients with NSCLC, in particular for those with EGFR-driven tumors who have either primary or acquired resistance to EGFR TKIs.
- Published
- 2012
22. 443 mTORC1 loss impairs epidermal adhesion and differentiation via ROCK activation downstream of TGF-β signaling
- Author
-
Akshay Sood, Bo Xiao, L. Elhelu, Tamara L. Lotan, Kaushal Asrani, C. Conover Talbot, Paul F. Worley, A. Fabiola, and A. Dubin
- Subjects
Downstream (manufacturing) ,Tgf β signaling ,Chemistry ,Cell Biology ,Dermatology ,mTORC1 ,Adhesion ,Molecular Biology ,Biochemistry ,Cell biology - Published
- 2017
23. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway
- Author
-
Simeon E. Goldblum, Keli J. Renoud, Maria Mochin-Peters, Antonino Passaniti, Jessica Bennett, David R. D'Souza, Maryann M. Salib, Kaushal Asrani, and Paul Shapiro
- Subjects
Transcriptional Activation ,medicine.medical_specialty ,endocrine system diseases ,Angiogenesis ,Core Binding Factor Alpha 1 Subunit ,Biology ,Biochemistry ,Receptor, IGF Type 1 ,Polyol pathway ,Aldehyde Reductase ,Internal medicine ,medicine ,Humans ,Insulin-Like Growth Factor I ,RNA, Small Interfering ,Receptor ,Autocrine signalling ,Extracellular Signal-Regulated MAP Kinases ,Molecular Biology ,Transcription factor ,Cells, Cultured ,Aldose reductase ,Wound Healing ,Mechanisms of Signal Transduction ,nutritional and metabolic diseases ,Endothelial Cells ,Cell Biology ,Endothelial stem cell ,Oxidative Stress ,Endocrinology ,Glucose ,Hyperglycemia ,Wound healing - Abstract
Diabetes mellitus accelerates cardiovascular microangiopathies and atherosclerosis, which are a consequence of hyperglycemia. The aldose reductase (AR) polyol pathway contributes to these microvascular complications, but how it mediates vascular damage in response to hyperglycemia is less understood. The RUNX2 transcription factor, which is repressed in diabetic animals, promotes vascular endothelial cell (EC) migration, proliferation, and angiogenesis. Here we show that physiological levels of glucose (euglycemia) increase RUNX2 DNA binding and transcriptional activity, whereas hyperglycemia does not. However, inhibition of AR reverses hyperglycemic suppression of RUNX2. IGF-1 secretion and IGF receptor phosphorylation by autocrine IGF-1 occur equally in euglycemic or hyperglycemic conditions, suggesting that reduced RUNX2 activity in response to hyperglycemia is not because of altered IGF-1/IGF receptor activation. AR also negatively regulates RUNX2-dependent vascular remodeling in an EC wounded monolayer assay, which is reversed by specific AR inhibition in hyperglycemia. Thus, euglycemia supports RUNX2 activity and promotes normal microvascular EC migration and wound healing, which are repressed under hyperglycemic conditions through the AR polyol pathway.
- Published
- 2009
24. Abstract 3866: TWEAK receptor (Fn14) Is a novel target in melanoma: Characterization of unique targeted therapeutics
- Author
-
Nhan L. Tran, Michele B. Weiss, Jeffrey A. Winkles, Hong Zhou, John W. Marks, Walter N. Hittelman, Sharron A.N. Brown, Keeley K. Phillips, Michael G. Rosenblum, Kaushal Asrani, Suhendan Ekmekcioglu, Emily Cheng, and Hideo Yagita
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,Cell growth ,Dacarbazine ,Melanoma ,medicine.disease ,Immunoconjugate ,Oncology ,Immunotoxin ,Cell surface receptor ,medicine ,Cancer research ,business ,Cytokine TWEAK ,V600E ,medicine.drug - Abstract
Previous studies have indicated that Fn14, the cell surface receptor for the cytokine TWEAK, is over-expressed in multiple human solid tumor types, including brain, breast, and lung cancers, and overexpression can be a negative prognostic indicator. We analyzed a series of melanoma cell lines and tumor tissue microarrays and detected Fn14 expression in ∼60% of the melanoma cell lines, including both B-Raf WT and B-Raf V600E lines. Fn14 expression was elevated in 178/190 (93.6%) of primary melanoma specimens and in 87/150 (58%) of melanoma metastases tested. Fn14 expression was not elevated in normal skin tissues. Initial development and characterization of an immunoconjugate designated ITEM4-rGel targeting Fn14 receptor has been published (Zhou et al., Mol. Cancer Ther. 10:1276 (2011)). We have now developed an Fn14-targeted immunotoxin more suitable for long-term clinical use. Specifically, we generated a humanized, dimeric single-chain version of ITEM-4 and fused this scFv to rGel. The resulting anti-Fn14 immunotoxin, designated hSGZ, bound to Fn14 with a Kd of ∼1.4 nM as determined by Biacore analysis. Confocal immunofluoresence studies showed that hSGZ specifically and rapidly (within 2 hrs) internalized into Fn14-expressing MDA-MB-435 melanoma cells. Cytotoxicity studies showed that hSGZ was highly cytotoxic to a panel of different melanoma cell lines (IC50 ranged from 0.1 pM to 1.1 nM) and was 2.2 to 2.8 ×105 fold more potent than free rGel. Treatment of cells expressing the multidrug resistance protein MDR1 showed no cross-resistance to the fusion construct in vitro. When hSGZ was combined with 5-FU, cisplatin, doxorubicin, etoposide or dacarbazine, we found an additive effect on melanoma cell growth inhibition. Mechanistic studies showed that hSGZ induced melanoma cell death consistent with a necrotic mechanism. Additionally, Fn14-targeted immunotoxins increased Fn14 expression and triggered cell signaling events similar to those induced by the TWEAK ligand. Finally, treatment of mice bearing human melanoma MDA-MB-435 and breast MDA-MB-231 xenografts with either ITEM4-rGel or hSGZ showed significant tumor growth inhibition compared to controls (P< 0.05). Fn14 appears to be an excellent new target for melanoma and the Fn14-targeting construct hSGZ appears to warrant further development as a novel therapeutic agent against Fn14-positive tumors. Melanoma lines appear to be the most sensitive tumor type tested but the reasons for this are unclear. Additional studies are in progress to investigate the biodistribution and pharmacokinetics of hSGZ in tumor-bearing mice. This work was conducted, in part, by the Clayton Foundation for Research (MGR); and supported by NIH grant NS055126 (JAW) and DOD Breast Cancer Concept Award BC086135 (JAW). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3866. doi:1538-7445.AM2012-3866
- Published
- 2012
25. Abstract 1216: The Fn14 receptor is highly expressed in NSCLC tumors and in NSCLC cell lines harboring EGFR-activating mutations
- Author
-
Galen Hostetter, Nathan M. Jameson, Glen J. Weiss, Landon J. Inge, Kaushal Asrani, Nhan L. Tran, Serdar Tuncali, Emily Cheng, Ross M. Bremner, and Jeffrey A. Winkles
- Subjects
Cancer Research ,Cancer ,Biology ,medicine.disease ,respiratory tract diseases ,T790M ,Gefitinib ,Oncology ,Immunology ,medicine ,Cancer research ,biology.protein ,Biomarker (medicine) ,Erlotinib ,Epidermal growth factor receptor ,Lung cancer ,Receptor ,medicine.drug - Abstract
Lung cancer is the leading cause of cancer deaths in the USA and worldwide and ∼85% of these cancers are of the non-small cell lung cancer (NSCLC) subtype. Approximately 10-15% of the NSCLC patients in the USA and 30-50% of these patients in Asia have tumors harboring somatic mutations in the epidermal growth factor receptor (EGFR) that cause constitutive activation of this receptor. These patients have the best clinical response to the small molecule EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Here we report that the TNF receptor superfamily member fibroblast growth factor-inducible 14 (Fn14) is frequently overexpressed in NSCLC tumors. We have also found that NSCLC cell lines that contain the same EGFR activating mutations found in patients express high levels of Fn14. Erlotinib treatment of these cells decreases Fn14 levels; therefore, EGFR signaling is indeed triggering Fn14 gene expression in these cell lines. Consistent with this proposal, when EGFR activation mutant receptors (L858R, ΔL747-E749, and D770-N771 insertion) were expressed in rat RL65 lung epithelial cells Fn14 expression was induced. In contrast, RL65 cells expressing a kinase-deficient EGFR receptor (D837A) did not show an increase in Fn14 expression. Since some NSCLC tumors with EGFR activating mutations acquire an additional EGFR mutation (T790M) that promotes TKI resistance, we examined Fn14 levels in a cell line containing both types of mutations. The Fn14 receptor was expressed at high levels in these cells. Finally, we found that shRNA-mediated Fn14 knockdown reduces NSCLC cell migration. Together, these data indicate that EGFR activation in NSCLC cells increases Fn14 gene expression and that Fn14 levels remain elevated in drug resistant cells. Furthermore, Fn14 may play a role in NSCLC cell motility. We propose that Fn14 may be a good biomarker for selection of NSCLC patients most likely to benefit from EGFR TKIs. It may also be a therapeutic target for NSCLC patients; in particular, for those patients with EGFR-driven tumors who have either primary or acquired resistance to EGFR tyrosine kinase inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1216. doi:10.1158/1538-7445.AM2011-1216
- Published
- 2011
26. Abstract 3169: HER2 signaling regulates Fn14 receptor expression in breast cancer cells
- Author
-
Jeffrey A. Winkles and Kaushal Asrani
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Receptor expression ,Cancer ,Biology ,Lapatinib ,medicine.disease ,medicine.disease_cause ,Breast cancer ,Cytokine ,Endocrinology ,Oncology ,Internal medicine ,medicine ,Cancer research ,Tumor necrosis factor alpha ,Signal transduction ,skin and connective tissue diseases ,Carcinogenesis ,medicine.drug - Abstract
Human epidermal growth factor receptor (HER)-2 overexpression occurs in ∼25% of all breast cancers and these cancers are frequently associated with increased metastases and poor survival. The molecular mechanisms underlying HER2 tumorigenesis are complex and multifactorial and a unified mechanism for HER2-mediated transformation has not emerged. However, HER2 requires HER3 to fulfill its oncogenic potential and the HER2-HER3 heterodimer functions as an oncogenic unit eliciting the most powerful mitogenic signal. Heregulin (HRG)-β1 is a natural ligand for HER3 and elicits the formation of potent HER2-HER3 heterodimers. HRG is expressed in ∼30% of breast tumors and is a risk factor for invasive breast cancer, independent of HER2. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a widely expressed cytokine of the tumor necrosis factor (TNF) superfamily that can regulate cell proliferation, migration, survival, differentiation and death. TWEAK acts via binding to fibroblast growth factor-inducible 14 (Fn14), the smallest known member of the TNF receptor superfamily. Fn14 is overexpressed in many human tumors, including breast tumors, where high expression levels strongly correlate with both the invasive HER2+/ER- intrinsic subtype and indicators of poor prognosis (Willis et al., Mol. Cancer Res. 6:725 (2008)). In consideration of this finding, we investigated whether HER2 activation in breast cancer cells could directly induce Fn14 gene expression. We found that transient or stable transfection of MCF-7 cells with a HER2 expression plasmid increased Fn14 protein expression as assayed by both Western blot and FACS analysis. Breast tumor tissue from HER2-transgenic mice also showed increased expression of Fn14, when compared with normal mammary gland. Furthermore, when MCF-7 cells were treated with HRG-β1, Fn14 protein expression was increased in a dose- and time-dependent manner. Both the HER2 overexpression-induced and the HRG-β1-induced increase in Fn14 expression in MCF-7 cells could be blocked by treatment with the small-molecule HER1/2 tyrosine kinase inhibitor lapatinib. Studies are in progress to elucidate the signaling pathways involved in the HER2-mediated increase in Fn14 expression, whether this increase is via a transcriptional or a post-transcriptional mechanism, and whether Fn14 may contribute to the increased proliferation and invasion that is associated with HER2/HER3-activated cells. Finally, since Fn14 and HER2 are frequently co-overexpressed in breast tumors, we hypothesize that Fn14 could be a new therapeutic target for those patients with HER2+ breast cancer that display either intrinsic or acquired resistance to HER2-targeted drugs. Research supported, in part, by Susan G. Komen for the Cure Research Grant KG081095 (JAW). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3169.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.